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Abstract
Ebola is an acute disease causing hemorrhagic fever marked with high mortality rate. 
The patients who suffer from Ebola only receive palliative care because there is no avail-
able drug which can consistently cure this disease. To date, no cure has been found to 
treat this disease. Bioinformatics and computer-aided drug discovery and development 
(CADDD) are employed to utilize the readily available genomic and proteomic data and 
enhance the hit rate of the novel and repurposed drug for Ebola therapy. Additionally, 
the time and cost of wet laboratory experiments can be drastically reduced by the support 
of bioinformatics approach. Our laboratory has succeeded not only in creating the bioin-
formatics research pipeline but also screening and developing the drug candidate to cure 
Ebola. Through pharmacophore-based virtual screening and molecular docking simula-
tions, we discovered that about three Indonesian natural product compounds have note-
worthy molecular interactions against EBOV VP35 protein, which are responsible for 
the RNA synthesis of the Ebola. These compounds can be reevaluated further through 
advances in in silico simulation and in vitro experiments.
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1. Introduction
Ebola, previously known as Ebola virus disease, is an acute viral infection causing hemor-
rhagic fever marked by high mortality rate in human and nonhuman primates [1]. It is a 
zoonotic disease transmitted by direct contact with mucosal tissue or bodily fluids (blood, 
feces, and other secreted fluids) of the infected living or dead human and animal [2–4]. The 
animal reservoir for this disease is still unknown. Fruit bat (Hypsignathus monstrosus, Epomops 
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franqueti, and Myonycteris torquata) which belongs to Pteropodidae family is suspected as the 
most likely host of Ebola, although the linkage has not been confirmed [5–7].
Ebola is an enveloped, nonsegmented, negative-sense, single-stranded RNA virus which 
belongs to Ebolavirus genus, Filoviridae family, and Mononegavirales order [8, 9]. Ebola virus 
(EBOV), Tai Forest virus (TAFV), Reston virus (RESTV), Sudan virus (SUDV), and Bundibugyo 
virus (BDBV) are the virus making up the Ebolavirus genus [10]. EBOV and SUDV come as the 
most frequent outbreak-causing virus which has the case-fatality rate of 76 and 55% (CI 95%), 
respectively [11]. On the other hand, RESTV causes death in primates such as gorillas and 
chimpanzees but not known to have caused disease in humans [12, 13].
The Ebola virus genomic RNA is consisted of around 19,000 nucleotides [14]. It encodes seven 
structural protein, namely, nucleoprotein (NP), glycoprotein (GP), RNA-dependent RNA 
polymerase (L), matrix protein (VP40), and three nucleocapsid proteins (VP24, VP30, and 
VP35) [15, 16]. It also encodes one nonstructural protein, the secretory glycoprotein (sGP) [17]. 
The genome is linearly arranged as follows: 3′-leader-NP-VP35-VP40-GP/sGP-VP30-VP24-L-
trailer-5′ [14, 17, 18].
The seven structural proteins and one nonstructural protein have an imperative role in Ebola 
virus life cycle [16]. NP: viral replication and scaffold for additional viral proteins. GP: binds 
to receptors on the cell surface and membrane fusion, pathogenicity. sGP: inhibits neutrophil 
function and adsorbs neutralizing antibodies. L: synthesis of positive-sense RNA. VP40: viral 
assembly and budding, structural integrity of viral particles, and maturation of the virion. 
VP24: nucleocapsid formation, encapsulates and shields viral genome from nucleases, viral 
replication. VP30: viral transcription activator. VP35: multi-virulence functionality, innate 
immune antagonist, and an RNAi silencing suppressor [16, 17].
The patient who suffers from Ebola shows no symptoms during the initial infection. After the 
incubation for about 4–10 days, the general symptoms such as fever, myalgia, and malaise 
and sometimes accompanied by chills appear. These symptoms often confused with dengue 
or malaria in tropical climates [3, 19]. As the infection progresses, the patient shows flu-like 
symptoms accompanied by gastrointestinal symptoms. In severe cases, Ebola developed into 
a conjunctival hemorrhage, epistaxis, melena, hematemesis, coagulation abnormalities, and 
a range of hematological irregularities. The neurological symptoms such as encephalopathy, 
convulsions, and delirium may also occur during the late stage of the infection [19, 20]. The 
patient dies around 6–9 weeks after the symptoms appear [21]. With the nonspecific symp-
toms, severe morbidity, and high mortality rate, the World Health Organization (WHO) has 
acknowledged Ebola as one of the most malignant diseases in the world [22].
The first recorded Ebola outbreak emerged in Sudan between June and November 1976. It 
mainly affected Nzara, Maridi, Tembura, and Juba where 150 of 284 victims died (the mortal-
ity rate of 53%) [2, 23]. After the first outbreak, 19 other outbreaks have occurred in Africa 
with the mean fatality rate of 65.4% [11].
The last and the most extensive Ebola outbreak was announced by the WHO on March 23, 
2014. This outbreak appears to have emerged in the Guéckédou district of the southeast 
region of Republic of Guinea [24–26]. The WHO announced the epidemic to be a Public 
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Health Emergency of International Concern (PHEIC) on August 8, 2014, due to the severe 
consequences if Ebola ever spread around the globe. PHEIC was disclosed because of the 
weak health services of Guinea, Liberia, Sierra Leone, and other neighboring countries at 
risk in combating Ebola and the continuing transmission with a high fatality rate of Ebola in 
West Africa [26]. When the outbreak ends in March 2016, Ebola has claimed 1310 lives out of 
28,616 reported cases [27, 28]. Even though the damage caused by the last outbreak of Ebola is 
calamitous, there is still no FDA-approved antiviral drug to treat this disease.
Ebola is considered as one of the neglected tropical diseases because the outbreaks take place 
in the poor populations with limited resources, mostly in West Africa [29]. The research and 
drug development for Ebola have been neglected for decades because the drug developers 
regard it as a commercially unattractive project to invest their resource. The negligence occurs 
to all tropical diseases by only 13 out of 1393 new approved drugs between 1975 and 1999 that 
were indicated for tropical disease [30]. However, the frequent outbreaks in the last decade 
and the massive outbreak which was occurred in 2014 have drawn much attention to drug 
development for Ebola [16]. Without available treatment or vaccine, paramedic only relied on 
palliative care for the infected patients and barrier methods to prevent the transmission [31]. 
Hence, the researchers investigating ways for helping people just infected with Ebola (treat-
ment) and preventing people to get infected when exposed to Ebola (vaccine) [32].
The conventional medical treatment for Ebola is a supportive care with intravenous fluids 
or oral rehydration with electrolyte solutions. The reason being that the virus interferes with 
blood clotting and disrupts electrolyte balance. Thus, such intervention can help to keep up 
the condition of the patient. However, such intervention is not enough for severely ill patients 
to sustain and recover [21, 32].
Zmapp, a combined humanized monoclonal antibody, was tested as a passive immuno-
therapy against Ebola. The preclinical test was conducted by Mapp Biopharmaceutical. 
This monoclonal antibody shows 100% efficacy in preventing lethal disease on cynomolgus 
macaques when treatment is initiated up to 5 days postinfection of EBOV [31].
Other experimental therapies developed a novel synthetic adenosine analog, BCX4430. This 
compound shows in vitro and in vivo activity by inhibiting viral RNA polymerase function, 
acting as a non-obligate RNA chain terminator. BCX4430 protects both mice and guinea pig 
models from a severe infection of Ebola virus and Marburg virus. In addition, this compound 
completely protects cynomolgus macaques from Marburg virus infection if administered as 
late as 48 h after infection [33].
Not only does the research focus on the development of a novel drug, but the research is also con-
ducted to identify potential repurposed therapeutic agents for the treatment of Ebola [34, 35]. 
Toremifene and clomiphene, the selective estrogen reuptake modulators, are currently 
known as the drug to treat breast cancer and infertility, respectively. Both drugs inhibit Ebola 
virus entry into the cell by preventing the late stage membrane fusion. These drugs show an 
inhibition activity by more than 90% in vitro. Higher dose than the standard clinical range is 
needed to achieve the therapeutic effect on Ebola. However, a higher dose would increase the 
risk of serious side effect of toremifene and clomiphene, which are electrolyte derangements 
and ocular adverse effect, respectively [36].
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Other experiments screen amiodarone, a multichannel ion blocker; sertraline, selective serotonin 
reuptake inhibitor; and bepridil, a calcium channel blocker as a repurposed therapeutic agent 
targeting Ebola. Amiodarone works by the induction of Niemann-Pick C-like phenotype that 
inhibits late endosomal entry of Ebola virus [37]. Sertraline and bepridil work in a similar fash-
ion to amiodarone. Both drugs show inhibition activity in an in vitro test by more than 90% [35].
Several vaccines have also been developed to prevent the Ebola. ChAd3-ZEBOV, which has 
developed by GlaxoSmithKline in collaboration with the US National Institute of Allergy and 
Infectious Diseases, is a chimpanzee-derived adenovirus vector with an Ebola virus gene 
inserted. This vaccine induced uniform protection against acute lethal Ebola virus in cyno-
molgus macaques. However, the protection of this vaccine declines over several months [38].
The other vaccine, which is developed by the Public Health Agency of Canada in Winnipeg, 
is rVSV-ZEBOV. It uses an attenuated vesicular stomatitis virus which has been genetically 
modified to express glycoprotein of Ebola virus. The rVSV-ZEBOV has undergone a ring vac-
cination phase 3 efficacy trial which assesses the protective activity of rVSV-ZEBOV against 
Ebola virus in human beings. The result shows that rVSV-ZEBOV offers substantial protec-
tion against Ebola virus infection. Both randomized and a non-randomized clusters of vac-
cinated individuals show no disease development from the challenge performed 10 days 
postvaccination [39].
The Center for Disease Control and Prevention considered Ebola virus as a tier 1 select agent 
because it possesses a considerable risk of intentional misuse with a severe threat to public 
health and safety [40]. Researchers need to fill the APHIS/CDC Form 1 in order to register 
for possession, use, and transfer of Ebola virus. All requirements including the availability of 
Biosafety Level (BSL) 4 laboratory and certified personnel are needed to get access to Ebola 
virus sample [41]. Thus, to get a suitable sample, researchers tend to move their experiments 
on the genetically modified virus that can express part of known Ebola virus genome because 
it is not subjected to select agent [42].
Genomic and proteomic data of Ebola virus has been collected each time the outbreak occurred 
and stored in the open source database. Also, the Ebola virus protein interaction with the cor-
responding drug lead through in vitro test has also been increased in the past decades. To 
date, the protein three-dimensional (3D) structure of Ebola virus NP, VP35, VP40, GP, VP30, 
and VP24 has been available in Protein Databank (PDB). In addition, the active site residues 
of each protein have also been identified, except for NP. L is the only Ebola virus protein with 
unavailable 3D structure and unidentified active site [16]. Thus, researchers use a bioinfor-
matics approach to utilize the readily available genomic and proteomic data to research drug 
design and discovery.
Computer-aided drug discovery and development (CADDD) is employed to accelerate hit 
identification, hit-to-lead selection, enhance absorption, distribution, metabolism, excretion, 
and toxicity (ADMET) profile and avoid another safety issue [43]. This approach is currently 
growing and adapted quickly by pharmaceutical industry and academia because it reduces 
the time and cost of drug research [44, 45]. Currently, 16 compounds (Aliskiren, Boceprevir, 
Captopril, Dorzolamide, Indinavir, LY-517717, Nolatrexed, NVP-AUY922, Oseltamivir, 
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Raltegravir, Ritonavir, Rupintrivir, Saquinavir, TMI-005, Tirofiban, and Zanamivir) are in 
clinical trial or have been approved for therapeutic use. These compounds are the examples 
of successful application of CADDD [46, 47]. Through CADDD, the hit rate of the novel and 
repurposed drug for Ebola therapy could be improved.
A consistently effective treatment for Ebola is currently not yet available. Present therapeutic 
options are directed at palliative and supportive care to maintain and prolong the patient life. 
The majority of treatment, novel or repurposed drug, have been developed, but none of them 
are entirely satisfactory. In attempts to find a drug in the treatment of Ebola, inhibitors tar-
geting EBOV VP35 have received little attention even though it has a critical function in host 
immune evasion and viral RNA synthesis. Our objective is to find the optimal in silico Ebola 
therapeutic agents which later will be implemented in the wet laboratory.
2. Our in silico method
In this chapter, we will discuss the result of our in silico approach against EBOV VP35, one 
of the viral protein of EBOV which is responsible for the viral RNA synthesis and as the 
RNAi silencing suppressor agents [48, 49]. Moreover, this protein was also being studied by 
Brown et al. in 2014, which discovered the actual pose of their selected inhibitors against the 
EBOV VP35 in their perspective binding site and also deposited their work in RCSB Protein 
Databank (PDB) through several PDB IDs [50]. Thus, their proteins can be used as the template 
for pharmacophore mapping model for our docking simulation approach. Moreover, we also 
deployed the Indonesian natural product compounds for virtual screening purpose to find 
the suitable lead compounds for combating Ebola. The reason for choosing the Indonesian 
natural product compounds because of Indonesia, as one of the largest megadiversity coun-
tries, has no less than 38,000 flowering plants that grow around the nation, with 55% of them 
are endemic plants [51, 52].
First, we prepared the Indonesian natural product compounds by searching the molecular 
structures through several journals and databases [53–69], after which we were drawing them 
using ChemBioDraw 14.0 software. From this step, we obtained about 3429 compounds in the 
process. All of these ligands were then protonated, washed, and minimized by using MOE 
2014.09 software [70]. These ligands were saved for the docking simulation purpose. For the 
EBOV VP35 protein, we selected the PDB ID: 4IBC as our protein, and we determined the 
pharmacophore site through standard protein-ligand interaction fingerprints (PLIF) protocol 
of MOE 2014.09 software. This step generated the pharmacophore model around the binding 
site of EBOV VP35 after we performed the protonating process of EBOV VP35 through “LigX” 
feature of MOE 2014.09 software. Later on, we conducted molecular docking simulation using 
the modification of our current approach [71, 72]. Instead of using “Triangle Matcher” and 
“London dG,” we used “Pharmacophore” and “Affinity dG” for “Placement” and “Rescoring 1” 
parameters to accommodate the pharmacophore model that created in an earlier phase, while 
the rest of parameters were set according to the default setup. First, the STD1 ligand (IUPAC 
name: 2-(4-(4-(2-chlorobenzoyl)-5-(2-chlorophenyl)-2,3-dioxo-2,3-dihydro-1H-pyrrol-1-yl) 
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phenyl)acetic acid) and 100 decoy ligands were docked into the binding site to validate the 
pharmacophore model. “Rigid Receptor” and “Induced-Fit” protocols were performed against 
the Indonesian natural product compounds and STD1 ligand later on.
In an attempt of searching the proper pharmacophore site in the binding site of EBOV VP35, 
we utilized the PLIF protocol from MOE 2014.09 software by using STD1 ligand as the tem-
plate. From this approach, we figured out that the binding site of EBOV VP35 protein consists 
of three pharmacophore sites, as it displayed in Figure 1. One hydrophobic spot is affili-
ated with Lys248 residues through arene-hydrogen interaction, while two H-bond acceptors, 
lone-pair sites, are connected with Gln241 and Lys251. These sites were responsible for the 
binding attachment of the STD01 ligand when bound to EBOV VP35 protein. Thus, it can be 
predicted that any ligands that bind to these residues may exhibit the same antiviral activities 
like STD01 ligand.
The pharmacophore sites were later validated by having the STD01 ligand and 100 decoys to 
be screened through molecular docking simulation. In this phase, we deployed “virtual screen-
ing” approach as our docking protocol, with pharmacophore model that was included in the 
simulation. After the screening was conducted, we discovered that all of the decoys did not pass 
the test, indicating this method was validated and did not create the “false-positive” ligand that 
may result during docking simulation. Furthermore, the STD01 ligand passed this test with a 
∆G
binding
 score of −5.2778 kcal/mol and RMSD value of 1.5487 Å. This result was shown that the 
parameters that were set earlier were decent enough to be reproduced in the next simulation. 
The comparison of the initial and screened poses of STD01 ligand is shown in Figure 2.
The pharmacophore-based docking simulation of EBOV VP35 protein was later performed 
against the 3429 Indonesian natural product ligands that were already prepared. From the 
simulations, we acquired 20 ligands that matched with the pharmacophore model of EBOV 
VP35, which means that other 3409 ligands did not possess the properties that needed to pass 
the initial pharmacophore screening. In the first docking simulation (Rigid Docking protocol), 
Figure 1. The pharmacophore model of the STD01 ligand in the binding site of EBOV VP35 protein. According to the 
PLIF feature of MOE 2014.09 software, the STD01 ligand comprises three pharmacophore sites: one hydrophobic point 
and two acceptor/lone-pair points (left). In the docking simulations, we deployed the “exclude points” to indicate the 
residues that exist in the VP35 binding site and prevent the larger ligands to interact with the binding site.
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we found four Indonesian natural product ligands, namely, multifloroside, myricetin 3-rob-
inobioside, kaempferol 3-(6G-malonylneohesperidoside), and theasaponin, which have the 
∆G
binding
 score lower than the STD01 ligand. The molecular structures of these ligands can be 
seen in Figure 3.
Figure 2. The binding interaction of the STD01 ligand and EBOV VP35 binding site. The 2D interaction after docking 
simulation is displayed in the left figure, while the right figure presents the difference between the initial pose (shown in 
yellow) and after the docking simulation was conducted (shown in pink).
Figure 3. The molecular structure of multifloroside (top left), myricetin 3-robinobioside (top middle), kaempferol 
3-(6G-malonylneohesperidoside) (top right), theasaponin (bottom left), and 2-(4-(4-(2-chlorobenzoyl)-5-(2-chlorophenyl)-
2,3-dioxo-2,3-dihydro-1H-pyrrol-1-yl)phenyl)acetic acid (bottom right).
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After the first docking simulation had been performed, the second docking simulation 
(Induced-Fit protocol) was utilized against these four proteins to revalidate the docking 
pose that was produced in the previous simulations. If the RMSD difference was lower 
than 2.0 Å, it means that the docking pose is good enough and may be reproduced in 
the actual simulation [73]. In this simulation, we found that multifloroside ligand has 
the lowest ∆G
binding
 score of −10.8405 kcal/mol, followed by myricetin 3-robinobioside 
(−10.0897 kcal/mol), kaempferol 3-(6G-malonylneohesperidoside) (−9.8721 kcal/mol), and 
theasaponin (−9.0175 kcal/mol). These results were significantly lower than the STD01 
ligand, which sits in −9.0175 kcal/mol. However, we must take into account that the RMSD 
value of multifloroside ligand was 3.2691 Å, higher than 2.0 Å; it means that the docking 
pose that was generated during the docking simulation was not acceptable. Meanwhile, 
Figure 4. The interacting residues of EBOV VP35 protein with myricetin 3-robinobioside (left), kaempferol 3-(6G-malony-
lneohesperidoside) (middle), and theasaponin (right).
Molecule name ∆G
binding
 (RMSD) H-bond interaction residues
Multifloroside −10.8405 kcal/mol
(3.2691)
Arg225, Tyr229, Lys 248, and 
Lys251
Myricetin 3-robinobioside −10.0897 kcal/mol
(1.2275)
Lys222, Arg225, Gln241, and 
Lys251
Kaempferol 3-(6G-malonylneohesperidoside) −9.8721 kcal/mol
(1.0311)
Gln241, Gln244, Lys251, and 
His296
Theasaponin −9.0175 kcal/mol
(0.4352)
Arg225, Gln241, and Lys251
STD01 ligand (standard) −8.4579 kcal/mol
(0.7747)
Gln241, Lys248, and Lys251
Table 1. The results of molecular docking simulation.
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the other three ligands possessed the tolerable RMSD value (1.2275, 1.0311, and 0.4352 Å 
for myricetin 3-robinobioside, kaempferol 3-(6G-malonylneohesperidoside), and theasa-
ponin, respectively). Furthermore, we also observed the interactions between the ligands 
and the binding site of EBOV VP35. From the docking simulation, we figured out that all 
three remaining ligands made interactions with Gln241 and Lys251, which are important 
in suppressing the EBOV VP35 activity. The full results of molecular docking simulations 
can be seen in Table 1 and Figure 4.
3. Conclusions
Without no doubt, the drug developments of Ebola are desperately needed due to high patho-
genicity and mortality rate that emitted by this disease. Through this chapter, we present that 
bioinformatics and CADDD, especially the pharmacophore-based drug design, may be the 
solution to significantly increase the viability of the newly discovered lead compounds that 
can be introduced as the drug candidate of Ebola virus, which can be supported later through 
in vitro study to validate the results that we found in previous research. The dry lab experi-
ments should play a significant role in the development of drugs, not only Ebola but also 
for all diseases due to low cost and not a time-consuming process. Therefore, the improve-
ments and developments of bioinformatics and CADDD should also speed up the time that 
we needed to obtain the drug candidates for our health problems.
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